These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31198186)

  • 21. Willingness to pay for a QALY: theoretical and methodological issues.
    Gyrd-Hansen D
    Pharmacoeconomics; 2005; 23(5):423-32. PubMed ID: 15896094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Life-cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost-benefit analysis?
    Bleichrodt H; Quiggin J
    J Health Econ; 1999 Dec; 18(6):681-708. PubMed ID: 10847930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeled cost-effectiveness of transforaminal lumbar interbody fusion compared with posterolateral fusion for spondylolisthesis using N(2)QOD data.
    Carreon LY; Glassman SD; Ghogawala Z; Mummaneni PV; McGirt MJ; Asher AL
    J Neurosurg Spine; 2016 Jun; 24(6):916-21. PubMed ID: 26895529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath.
    Harnan SE; Tappenden P; Essat M; Gomersall T; Minton J; Wong R; Pavord I; Everard M; Lawson R
    Health Technol Assess; 2015 Oct; 19(82):1-330. PubMed ID: 26484874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).
    Mehrez A; Gafni A
    Pharmacoeconomics; 1992 May; 1(5):338-45. PubMed ID: 10146998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.
    Beresniak A; Medina-Lara A; Auray JP; De Wever A; Praet JC; Tarricone R; Torbica A; Dupont D; Lamure M; Duru G
    Pharmacoeconomics; 2015 Jan; 33(1):61-9. PubMed ID: 25230587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health State Values Derived from People with Multiple Sclerosis for a Condition-Specific Preference-Based Measure: Multiple Sclerosis Impact Scale-Eight Dimensions-Patient Version (MSIS-8D-P).
    Goodwin E; Green C; Hawton A
    Value Health; 2018 Nov; 21(11):1338-1345. PubMed ID: 30442282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Not all "quality-adjusted life years" are equal.
    Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
    J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
    Leung VC; Pechlivanoglou P; Chew HF; Hatch W
    Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The quality of reporting in published cost-utility analyses, 1976-1997.
    Neumann PJ; Stone PW; Chapman RH; Sandberg EA; Bell CM
    Ann Intern Med; 2000 Jun; 132(12):964-72. PubMed ID: 10858180
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?
    Gabriel SE; Kneeland TS; Melton LJ; Moncur MM; Ettinger B; Tosteson AN
    Med Decis Making; 1999; 19(2):141-8. PubMed ID: 10231076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
    Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
    Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory.
    Lipman SA; Brouwer WBF; Attema AE
    Value Health; 2019 Jul; 22(7):816-821. PubMed ID: 31277829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality-adjusted life years, utility theory, and healthy-years equivalents.
    Mehrez A; Gafni A
    Med Decis Making; 1989; 9(2):142-9. PubMed ID: 2501627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating sign-dependence in health-related social welfare functions.
    Attema AE
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):223-8. PubMed ID: 25543906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.
    Nimdet K; Ngorsuraches S
    BMJ Open; 2015 Oct; 5(10):e008123. PubMed ID: 26438135
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.